Analysts predict that Endocyte, Inc. (NASDAQ:ECYT) will announce earnings of ($0.21) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Endocyte’s earnings, with estimates ranging from ($0.23) to ($0.19). Endocyte also reported earnings of ($0.21) per share during the same quarter last year. The business is scheduled to report its next earnings results on Wednesday, November 8th.

On average, analysts expect that Endocyte will report full-year earnings of ($0.93) per share for the current fiscal year, with EPS estimates ranging from ($0.97) to ($0.89). For the next financial year, analysts expect that the business will post earnings of ($0.81) per share, with EPS estimates ranging from ($0.82) to ($0.80). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Endocyte.

Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.03. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. The company had revenue of $0.01 million during the quarter. During the same period last year, the business earned ($0.25) EPS.

Several analysts have recently commented on ECYT shares. Zacks Investment Research upgraded Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, May 19th. Cowen and Company downgraded Endocyte from an “outperform” rating to a “market perform” rating in a research note on Friday, June 2nd. Wedbush downgraded Endocyte from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a research note on Monday, June 5th. Finally, ValuEngine downgraded Endocyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.58.

Several hedge funds have recently modified their holdings of ECYT. Algert Global LLC purchased a new stake in shares of Endocyte during the first quarter valued at approximately $345,000. Teachers Advisors LLC increased its stake in shares of Endocyte by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 9,506 shares in the last quarter. Stoneridge Investment Partners LLC increased its stake in shares of Endocyte by 40.0% in the first quarter. Stoneridge Investment Partners LLC now owns 57,406 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16,399 shares in the last quarter. RMB Capital Management LLC increased its stake in shares of Endocyte by 8.8% in the first quarter. RMB Capital Management LLC now owns 264,885 shares of the biopharmaceutical company’s stock valued at $681,000 after buying an additional 21,500 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Endocyte by 2.7% in the fourth quarter. State Street Corp now owns 620,248 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 16,289 shares in the last quarter. Institutional investors own 28.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Anticipate Endocyte, Inc. (ECYT) to Announce -$0.21 EPS” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/30/analysts-anticipate-endocyte-inc-ecyt-to-announce-0-21-eps.html.

Endocyte (NASDAQ ECYT) opened at 1.39 on Wednesday. The company has a 50 day moving average price of $1.39 and a 200-day moving average price of $1.97. Endocyte has a 52-week low of $1.17 and a 52-week high of $3.49. The firm’s market cap is $59.18 million.

About Endocyte

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.